Inventor · disambiguated record
Lusong Luo
Also filed as: LUO LUSONG
4 granted patents·6 pending applications·24 citations·filing 2017–2025
73Inventor score
Top patents by PatentIndex Score
10 records- 0193US10864203B2Combination of a PD-1 antagonist and a RAF inhibitor for treating cancerBEIGENE LTD·Filed 2017·Granted Dec 15, 2020·10 cites·13 claims
- 0292US11202782B2Treatment cancers using a combination comprising PARP inhibitorsBEIGENE LTD·Filed 2017·Granted Dec 21, 2021·9 cites·29 claims
- 0384US11701357B2Treatment of B cell cancers using a combination comprising Btk inhibitorsBEIGENE SWITZERLAND GMBH·Filed 2017·Granted Jul 18, 2023·4 cites·19 claims
- 0484US11534431B2Combination of a PD-1 antagonist and a RAF inhibitor for treating cancerBEIGENE LTD·Filed 2020·Granted Dec 27, 2022·1 cites·21 claims
- 0569US2023364096A1Use of a combination comprising a btk inhibitor for treating cancersBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 0663US2025090507A1Methods of Treating Cancer With a B-RAF InhibitorMAPKURE LLC·Filed 2024·Application pending·0 cites
- 0752US2023128315A1Co-administration of mirdametinib and lifirafenib for use in treating cancersBEIGENE LTD·Filed 2021·Application pending·0 cites
- 0847US2020155567A1Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapyBEIGENE LTD·Filed 2018·Application pending·0 cites
- 0945US2025221970A1Combinations of a B-RAF Inhibitor and an Anti-EGFR Antibody for the Treatment of CancerMAPKURE LLC·Filed 2025·Application pending·0 cites
- 1041US2019170752A1Method for predicting efficacy of immune checkpoint inhibitors in cancer patientsBEIGENE LTD·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lusong Luo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →